Express develops tumor-infiltrating lymphocyte therapy to treat solid tumors, Xinrui receives US$115 million in assistance

▎Editor of WuXi AppTec's content team On September 9, 2021, Obsidian Therapeutics announced the completion of a US$115 million Series B financing
.

The funds obtained in this round of financing will be used to promote Obsidian's main tumor infiltrating lymphocyte (TIL) project cytoTIL15 into the clinic to obtain the first batch of clinical trial data for the treatment of metastatic melanoma
.

In addition, Obsidian also plans to rapidly expand cytoTIL15 to other solid tumors
.

TIL is a tumor-infiltrating lymphocyte isolated from a patient's tumor tissue, which is expanded in vitro and then infused back into the patient's body
.

Usually, patients need to receive IL-2 cytokine therapy at the same time to promote the proliferation of TIL in the body, but IL-2 has strong side effects
.

cytoTIL15 is Obsidian's leading cytoTIL project and is currently in the preclinical development stage for the treatment of metastatic melanoma and other solid tumors
.

Its unique feature is the use of genetic engineering to allow TIL cells to express IL-15 bound to the cell membrane
.

After the TIL cells are imported into the patient's body, the patient is no longer required to receive IL-2 treatment, which improves the durability of the TIL therapy and reduces the toxic side effects of the therapy
.

Moreover, using the company's unique cytoDRiVE technology, the expression level of IL-15 is controlled by FDA-approved small molecule drugs, which improves the safety of the therapy
.

▲Obsidian’s cytoTIL project pipeline (picture source: Obsidian’s official website) Mr.
Paul Wotton, CEO of Obsidian, said: “This funding will help us continue to advance the transformational therapy cytoTIL15 into clinical trials to treat patients with solid tumors, and further Expand our engineered TIL therapy pipeline
.

"Reference: [1] Obsidian Therapeutics Announces Closing of $115 Million Series B Financing.
Retrieved September 9, 2021, from https:// therapeutics-announces-closing-of-115-million-series-b-financing-301372195.
htmlDisclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a treatment recommendation either
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.